Several other research firms also recently commented on MOR. Goldman Sachs Group downgraded shares of Metcash from a conviction-buy rating to a neutral rating in a research note on Monday, June 24th. Berenberg Bank reaffirmed a hold rating and set a GBX 1,581 ($20.66) price objective on shares of in a research report on Tuesday, June 11th. Deutsche Bank cut shares of Mitsubishi Motors from a buy rating to a hold rating in a research report on Thursday, May 9th. Independent Research set a €96.00 ($111.63) price objective on shares of MorphoSys and gave the stock a neutral rating in a research report on Thursday, July 4th. Finally, Royal Bank of Canada upped their price objective on shares of from GBX 2,400 ($31.36) to GBX 2,800 ($36.59) and gave the stock an outperform rating in a research report on Monday, June 24th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of €101.67 ($118.22).
MOR stock opened at €100.70 ($117.09) on Tuesday. The company has a debt-to-equity ratio of 8.65, a current ratio of 7.75 and a quick ratio of 7.53. The company has a 50-day simple moving average of €87.84. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €124.90 ($145.23). The firm has a market capitalization of $3.18 billion and a P/E ratio of -54.20.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.